Franklin Genomic Advancements ETF Rating $29.93 +2.77 (+10.21%) Closing price 08/22/2025 03:55 PM EasternExtended Trading$29.93 0.00 (0.00%) As of 08/22/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsBuy This Stock Franklin Genomic Advancements ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HELX Aggregate RatingModerate Buy 2.77Holdings in HELX have an aggregate rating of Moderate Buy based on 362 analyst ratings issued in the past year covering 22 companies (63.6% of the portfolio).HELX Aggregate Price Target$29.93High Prediction$29.93Average Prediction$29.93Low Prediction$29.93Holdings in HELX have an aggregate price target of $29.93 and a range of $29.93 to $29.93 covering 22 companies (63.6% of the portfolio).HELX Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy5 Buy rating(s)Moderate Buy15 Moderate Buy rating(s)Hold1 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Franklin Genomic Advancements ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 22 HELX Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.28%NTRANatera$165.60+2.3%3.3977 of 5 stars3.06$193.19 16.7%18Positive News4.53%ALNYAlnylam Pharmaceuticals$454.38-2.8%4.1754 of 5 stars2.85$405.33 -10.8%26News CoverageInsider Trade4.38%MEDPMedpace$463.64+2.3%4.3461 of 5 stars1.93$406.60 -12.3%14News CoveragePositive NewsInsider Trade4.26%VRTXVertex Pharmaceuticals$395.12-0.6%4.9586 of 5 stars2.56$497.10 25.8%27Positive NewsAnalyst Downgrade3.77%KRYSKrystal Biotech$150.49+3.3%4.7241 of 5 stars3.00$210.38 39.8%9Trending NewsAnalyst Forecast3.53%INSMInsmed$131.88-0.5%4.005 of 5 stars2.94$132.57 0.5%17Trending NewsAnalyst ForecastInsider TradeAnalyst Revision3.34%GHGuardant Health$61.40+0.2%3.2234 of 5 stars3.06$57.50 -6.4%17News CoveragePositive News3.21%CTVACorteva$73.32+0.5%4.3562 of 5 stars2.87$80.25 9.5%15Positive News3.06%LLYEli Lilly and Company$710.73+0.1%4.9993 of 5 stars2.65$950.17 33.7%23Trending NewsAnalyst Upgrade2.91%AZNAstraZeneca$80.97+0.6%2.9507 of 5 stars2.80$86.00 6.2%5Positive News2.77%BBIOBridgeBio Pharma$49.08-2.3%4.6759 of 5 stars3.00$61.35 25.0%17Insider Trade2.70%CDNSCadence Design Systems$349.63+0.6%4.2954 of 5 stars2.73$364.33 4.2%15Trending NewsAnalyst UpgradeShort Interest ↑Analyst Revision2.59%BNTXBioNTech$110.88+0.1%1.7717 of 5 stars2.76$135.80 22.5%172.56%UTHRUnited Therapeutics$312.23+0.5%4.9245 of 5 stars2.69$382.00 22.3%13Insider TradeAnalyst Revision2.19%REGNRegeneron Pharmaceuticals$589.48-1.5%4.8505 of 5 stars2.81$829.65 40.7%26Positive NewsDividend Announcement1.96%TMOThermo Fisher Scientific$500.24+3.4%4.9157 of 5 stars2.73$593.00 18.5%22Trending NewsInsider TradeAnalyst Revision1.87%DHRDanaher$211.71+3.8%4.7344 of 5 stars2.85$247.61 17.0%20News CoveragePositive News1.85%LGNDLigand Pharmaceuticals$159.08+1.1%4.1245 of 5 stars3.00$157.00 -1.3%6Positive NewsShort Interest ↓1.82%QGENQiagen$49.71+1.2%3.8199 of 5 stars2.27$49.69 -0.1%111.75%ADPTAdaptive Biotechnologies$13.00+2.9%2.4179 of 5 stars2.88$12.38 -4.8%8News CoverageAnalyst Revision1.68%TEMTempus AI$80.52+5.0%1.7751 of 5 stars2.50$67.64 -16.0%12Trending NewsAnalyst ForecastInsider Trade1.62%EXASExact Sciences$47.47+1.7%4.932 of 5 stars2.92$67.43 42.0%24Positive News This page (BATS:HELX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access